Navigation Links
InterMune to Present at Goldman Sachs Healthcare Conference
Date:6/3/2009

BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York on June 9, 2009 at 2:35 p.m. ET.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Paula, CA (PRWEB) September 15, 2014 ... long term implantable silicones for the medical device ... responsive silicone gel for the implantable medical device ... a unique crosslink technology delivering a silicone gel ... The Dual Matrix technology consists of two ...
(Date:9/15/2014)... Rome, GA (PRWEB) September 15, 2014 ... ( http://www.hydrodynamics.com ) announced today that it will ... Verdes Estates, CA ( http://www.proteaf.com ) for implementing ... in high value continuous processing. Continuous flow ... in the chemical, pharmaceutical and petrochemical markets for ...
(Date:9/12/2014)... a magnet using an electric field (magnetoelectric memory ... the next-generation technology for information processing and storage. ... effect, due to the coexistence of electric and ... of spontaneous electric and magnetic polarizations is rare ... of the MEM effect. This article briefly reviews ...
(Date:9/12/2014)... , September 12, 2014 On Thursday, ... 0.12%, the Dow Jones Industrial Average finished the day 0.12% ... up 0.09%. The gains were broad based as seven out ... 500 Health Care Sector Index ended the day at 741.83, ... last one month. Investor-Edge has initiated coverage on the following ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... , , , For purification of up to 10 mg ultrapure plasmid , ... for efficient , purification of plasmid DNA , , ... benefits , , ... by 2x CsCl-gradient centrifugation , , ...
... , , , , , ... Svegliati, Michele Luchetti, and Armando Gabrielli , Laboratorio ... Scientifico, Ancona, Italy , , ... GC-rich sequences difficult to amplify by PCR. This article ...
... , , , QIAGEN introduces the ... automated, high-throughput DNA purification , from high-copy plasmids. ... for a lysate clearing step. Plasmid DNA purification is performed using ... procedure. The protocol , is faster and easier ...
Cached Biology Technology:Successful PCR amplification and subcloning of a GC-rich DNA fragment 2Successful PCR amplification and subcloning of a GC-rich DNA fragment 3Successful PCR amplification and subcloning of a GC-rich DNA fragment 4Successful PCR amplification and subcloning of a GC-rich DNA fragment 5DirectPrep 96 Miniprep System for cost-effective, high-throughput plasmid , DNA purification 2DirectPrep 96 Miniprep System for cost-effective, high-throughput plasmid , DNA purification 3DirectPrep 96 Miniprep System for cost-effective, high-throughput plasmid , DNA purification 4
(Date:9/15/2014)... 2014: Globally, cardiovascular disease (CVD) claims 17 million lives ... an additional 9.4 million. 1 New research presented ... Congress in Montpellier, France on September 15, 2014, suggests ... role. , At the Milk and Dairy ... milk and risk for hypertension and CVD was examined ...
(Date:9/15/2014)... available in German . ... the fossil energy carrier natural gas offers a variety ... Nevertheless, a consequent market penetration is still pending because ... Scientists of the Helmholtz Centre for Environ-mental Research (UFZ) ... Members of the IEA Task 37 (Energy from Biogas) ...
(Date:9/12/2014)... , Sept. 12, 2014 Research and ... "Global IC Card Management System Industry Report 2014" ... IC Card Management System Industry Report 2014 is a ... the global IC card management system. The ... definitions, classifications, applications and industry chain structure. The IC ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2The biomethane market needs clear frame conditions for further growth 2The biomethane market needs clear frame conditions for further growth 3Global IC Card Management System Industry Report 2014 2
... LSU,s Sibel Bargu, along with her former graduate student Ana ... LSU,s School of the Coast & Environment, has discovered toxic ... the first time. The recent findings were published in the ... journals, the Proceedings of the National Academy of Sciences ...
... dioxide injected deep underground to help fight climate change could ... up levels of contaminants in the water tenfold or more ... scientists. Based on a year-long analysis of core samples ... contamination is real, but there are ways to avoid or ...
... 9, 2010 For Immediate Release Scientists from ... identified for the first time a novel mechanism that ... body,s natural 24-hour physiological cycle. These new findings could ... shift work, and sleep disturbances, but also for disorders ...
Cached Biology News:LSU oceanography researcher discovers toxic algae in open water 2LSU oceanography researcher discovers toxic algae in open water 3Leaking underground CO2 storage could contaminate drinking water 2Scripps Research scientists identify new mechanism regulating daily biological rhythms 2Scripps Research scientists identify new mechanism regulating daily biological rhythms 3
...
Request Info...
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
... Synthetic peptide derived from the C-terminal ... Math-2. Specificity: Specific for the ... (positive controls: human U251 A172 IMR-32 ... rat brain homogenates)Storage: Store at -20C ...
Biology Products: